Home Blog Page 3

Peterhouse Investments Disclosure of Usha Martin Limited Share Sale

By
InvestyWise News
-

Peterhouse Investments Limited has disclosed the sale of 79,205 equity shares of Usha Martin Limited. This sale alters their holdings to 3,970,795 equity shares, representing 1.30% of the total share/voting capital. The transaction was executed on November 24, 2025, through the National Stock Exchange. This disclosure follows regulatory requirements for substantial acquisitions of shares and takeovers.

Shareholding Disclosure

Peterhouse Investments Limited has reported a change in its shareholding of Usha Martin Limited. The disclosure, dated November 24, 2025, reveals the details of equity shares sold through the open market.

Details of the Transaction

The transaction involved the sale of 79,205 equity shares. Following this sale, Peterhouse Investments Limited now holds 3,970,795 equity shares in Usha Martin Limited. This accounts for 1.30% of the total share/voting capital, and the same percentage of the total diluted share/voting capital. The sale was executed via the National Stock Exchange.

Impact on Shareholding

Before this transaction, the company held 4,050,000 equity shares, representing 1.33% of both the total share/voting capital and total diluted share/voting capital.

Source: BSE

Tata Communications Issues Commercial Paper Amounting to ₹200 Crore

By
InvestyWise News
-

Tata Communications Limited has issued and allotted Commercial Paper aggregating to ₹200 crore. The Commercial Paper is listed on the National Stock Exchange of India Limited. The date of issue is November 21, 2025, and the date of redemption is February 20, 2026. The discount rate is 6.05% p.a.

Commercial Paper Issuance

Tata Communications Limited has announced the issuance and allotment of Commercial Paper amounting to ₹200 crore.

Key Details of the Issuance

<

Security: Commercial Paper

Size of the Issue: ₹200 crore

Date of Issue: November 21, 2025

Date of Redemption: February 20, 2026

Face Value per Security: ₹5,00,000/-

Discount Rate: 6.05% p.a.

ISIN: INE151A14222

Listing

The Commercial Paper is listed on the National Stock Exchange of India Limited as of November 24, 2025.

Source: BSE

SAMMAAN Capital Timely Interest Payment on Secured NCDs

By
InvestyWise News
-

SAMMAAN Capital has confirmed the timely payment of interest on its Secured Redeemable Non-Convertible Debentures (NCDs) listed on the stock exchange. The company has successfully made the interest payments as of November 24, 2025, ensuring compliance and fulfilling its obligations to its debenture holders. This announcement reaffirms SAMMAAN Capital’s commitment to its financial responsibilities and investor relations.

Interest Payment Details

SAMMAAN Capital has announced that it has made timely interest payments on its Secured Redeemable Non-Convertible Debentures (NCDs). The payments were successfully completed on November 24, 2025.

Specific NCD Payments

The interest payments pertain to several series of NCDs. Key details include:

  • INE148I07UI0: Issue Size 536.41 INR lacs, Interest Amount 4.21472 INR lacs
  • INE148I07UD1: Issue Size 38 INR lacs, Interest Amount 0.29111 INR lacs
  • INE148I07UC3: Issue Size 1527.45 INR lacs, Interest Amount 12.29880 INR lacs
  • INE148I07UJ8: Issue Size 25 INR lacs, Interest Amount 0.19640 INR lacs
  • INE148I07UN0: Issue Size 937.30 INR lacs, Interest Amount 7.72946 INR lacs
  • INE148I07UR1: Issue Size 152.39 INR lacs, Interest Amount 1.29816 INR lacs
  • INE148I07UU5: Issue Size 2 INR lacs, Interest Amount 0.01665 INR lacs
  • INE148I07UV3: Issue Size 1484.19 INR lacs, Interest Amount 12.92063 INR lacs

All interest payments were made against the due date of November 25, 2025, with a record date of November 10, 2025.

Redemption Details

The announcement also indicates that there are no current redemption details available (NA).

Source: BSE

Eris Lifesciences Acquires Remaining Stake in Swiss Parenterals & Announces Preferential Issue

By
InvestyWise News
-

Eris Lifesciences will acquire the remaining 30% stake in its subsidiary, Swiss Parenterals Limited, making it a wholly-owned subsidiary. The acquisition is valued at INR 423.30 crore, to be discharged through a preferential issue of 23,06,372 equity shares. The company also plans a postal ballot to obtain shareholder approval for the preferential issue.

Full Ownership of Swiss Parenterals

Eris Lifesciences has announced its decision to acquire the remaining 30% stake in Swiss Parenterals Limited, thereby achieving 100% ownership of the company. This strategic move aims to enhance operational synergy and strengthen the company’s long-term strategic presence. The Board of Directors approved the acquisition on November 24, 2025.

Deal Rationale

The acquisition is expected to provide complete managerial control, enable full financial consolidation, improve cost efficiencies, and streamline governance. Eris Lifesciences anticipates that this consolidation will enhance shareholder value.

Preferential Issue Details

The consideration for the acquisition, amounting to INR 423.30 crore, will be discharged through the issuance of up to 23,06,372 equity shares of Eris Lifesciences on a preferential basis. These shares will be issued to Mr. Naishadh Shah, a director of Swiss Parenterals. The issue price is determined based on an independent valuation report.

Postal Ballot for Shareholder Approval

Eris Lifesciences will seek shareholder approval via postal ballot for the issuance of shares on a preferential basis to Mr. Naishadh Shah. The cut-off date for determining eligible members for e-voting is set for November 21, 2025.

Swiss Parenterals Performance

Swiss Parenterals, a subsidiary specializing in parenterals, has demonstrated robust performance over the past three fiscal years:

  • FY 2022-23: Turnover of INR 220.80 crore
  • FY 2023-24: Turnover of INR 282.97 crore
  • FY 2024-25: Turnover of INR 351.11 crore

The entity has a presence in over 80 countries.

Source: BSE

Eris Lifesciences Acquires Remaining Stake in Swiss Parenterals

By
InvestyWise News
-

Eris Lifesciences is set to acquire the remaining 30% stake in its subsidiary, Swiss Parenterals Limited, for ₹423.30 crore. The consideration will be discharged through the issuance of Eris Lifesciences equity shares on a preferential basis. The move aims to fully consolidate operations, enhance synergy, and achieve complete managerial control over Swiss Parenterals. The transaction is expected to close tentatively before March 31, 2026.

Swiss Parenterals Acquisition

Eris Lifesciences has announced the acquisition of the remaining 30% share capital of Swiss Parenterals Limited (“Swiss”). This acquisition will make Swiss Parenterals a wholly owned subsidiary of Eris Lifesciences. The announcement was made on November 24, 2025, following a Board of Directors meeting.

Transaction Details

The acquisition will be completed at a cost of ₹423.30 crore. The consideration will be discharged by Eris Lifesciences through the issuance of up to 2,306,372 equity shares of the company on a preferential basis. This will be issued to Mr. Naishadh Shah, a Director of Swiss Parenterals.

Strategic Rationale

The primary objective of this acquisition is to fully consolidate its position, enhance operational synergy, and strengthen its long-term strategic presence. By acquiring 100% ownership of Swiss, Eris Lifesciences expects to achieve complete managerial control, enable full financial consolidation, improve cost efficiencies, streamline governance, and contribute to enhanced shareholder value.

Swiss Parenterals Overview

Swiss Parenterals is involved in the Parenterals business. Incorporated on February 4, 1997, Swiss Parenterals has a strong presence in ~80+ countries. The turnover for the last three financial years is as follows:

* FY 2022-23: ₹220.80 Crores
* FY 2023-24: ₹282.97 Crores
* FY 2024-25: ₹351.11 Crores

Preferential Allotment

As part of the acquisition, Eris Lifesciences will issue up to 2,306,372 fully paid-up equity shares at a price of ₹1,835.35 per share to Mr. Naishadh Shah. This price has been determined based on an independent valuation report dated November 24, 2025.

Source: BSE

Union Bank Timely Interest Payment on Bonds

By
InvestyWise News
-

Union Bank has announced the timely payment of annual interest on its bonds as of November 24, 2025. The interest payment, amounting to ₹ 174,00,00,000/-, was made to bondholders as per the beneficiary position on the record date. This confirms the bank’s adherence to its financial obligations and commitment to investors.

Interest Payment Details

Union Bank has confirmed the timely payment of annual interest on its bonds. The key details are as follows:

  • ISIN: INE692A08169
  • Issue Size: Rs. 2,000 Crores
  • Interest Amount: Rs. 174,00,00,000/-
  • Frequency: Yearly
  • Due Date: 22.11.2025
  • Actual Payment Date: 24.11.2025
  • Last Interest Payment Date: 22.11.2024

The interest payment record date was 07.11.2025. The bank clarified that if any coupon payment date falls on a non-business day, the payment would be made on the next business day. Accordingly, the payment was made on 24.11.2025 instead of 22.11.2025.

Source: BSE

Nestlé India Analyst/Institutional Investor Meet Scheduled for November 28, 2025

By
InvestyWise News
-

Nestlé India has announced an analyst/institutional investor meet to be held on November 28, 2025. The meeting, featuring Goldman Sachs India Consumer Forum 2025, will be conducted virtually as a conference. No unpublished price-sensitive information will be shared during the meeting. This event allows investors insights into the company’s performance and strategies.

Upcoming Investor Conference

Nestlé India will participate in an analyst/institutional investor conference scheduled for November 28, 2025. The event is being hosted by Goldman Sachs India Consumer Forum 2025.

Virtual Conference Details

The investor meet will be held virtually, enabling participation from a wide range of analysts and institutional investors. Nestlé India has confirmed that the meeting is structured as a conference.

Important Notice

The company has explicitly stated that no unpublished price-sensitive information will be disclosed or discussed during the investor conference.

Source: BSE

HUDCO Signs MoU with National Institute of Urban Affairs

By
InvestyWise News
-

Housing and Urban Development Corporation (HUDCO) has signed a Memorandum of Understanding (MoU) with the National Institute of Urban Affairs (NIUA) on November 24, 2025. The MoU aims to develop programmes related to urban infrastructure and investment, including HUDCO’s Urban Invest Window (UiWIN). Both parties will collaborate on capacity building, research, and exploring funding opportunities.

Strategic Collaboration for Urban Development

HUDCO and NIUA have entered into a partnership formalized by a Memorandum of Understanding (MoU) signed on November 24, 2025. This collaboration aims to leverage the strengths of both organizations to enhance urban infrastructure development. The primary focus is on investment, training, research, and capacity building activities within the urban sector.

Key Areas of Cooperation

The MoU outlines several key areas of mutual cooperation between HUDCO and NIUA:

  • Developing programmes of mutual interest related to urban infrastructure and development, including HUDCO’s Urban Invest Window (UiWIN).
  • Organizing capacity building programs, seminars, conferences, and workshops.
  • Conducting research, monitoring, evaluation, and impact studies.
  • Exploring collaborations with multi-lateral funding agencies.

Focus on Infrastructure and Investment

The partnership intends to foster development in themes related to urban infrastructure, including infrastructure investment. The collaboration seeks to explore opportunities with multi-lateral funding agencies to further support urban development initiatives. The MoU is valid for 5 years from the date of execution, ensuring a sustained commitment to these collaborative goals.

Source: BSE

Hexaware Technologies Pledge of Equity Shares by CA Magnum Holdings

By
InvestyWise News
-

Hexaware Technologies announced a pledge of equity shares by CA Magnum Holdings. A Mauritian law fixed and floating charge will be applied to the shares held by CA Silkie Investments in CA Magnum Holdings. This action is in favor of The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch, acting as the offshore security agent. The announcement was made on November 24, 2025.

Pledge of Equity Shares

A pledge has been initiated on the equity shares of Hexaware Technologies. This involves a Mauritian law fixed and floating charge over shares of CA Magnum Holdings. The charge will be applied to equity shares held by CA Silkie Investments in CA Magnum Holdings.

Details of the Arrangement

The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch, is acting as the offshore security agent. This is for the benefit of the Secured Parties. It secures the Secured Obligations as defined in the Share Charge Agreement and Amended and Restated Facilities Agreement. The date of the share charge agreement is November 18, 2025. The effective date of the provisions of the Amended and Restated Facilities Agreement is November 17, 2025.

Key Entities Involved

  • CA Magnum Holdings
  • CA Silkie Investments
  • The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch

Impact on Share Capital

The total equity share capital before and after the acquisition/sale remains at 60,90,06,992 equity shares of Rs. 1 each. Total shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others) is 45,39,88,884, representing 74.55% of the total share/voting capital.

Source: BSE

CM Airtime Promotion Increase in Shareholding of Chambal Fertilisers

By
InvestyWise News
-

CM Airtime Promotion LLP has announced an increase in its shareholding in Chambal Fertilisers & Chemicals Ltd. The company purchased 17,000 equity shares on November 21, 2025, raising its total holdings to 595,073 shares. This acquisition reflects a minor increase in the overall percentage of shareholding, positioning the firm with a slightly larger stake in the fertiliser company.

Shareholding Update

CM Airtime Promotion LLP reports that they have acquired an additional 17,000 equity shares of Chambal Fertilisers and Chemicals Ltd. on November 21, 2025.

Revised Stake

Following the recent transaction, CM Airtime Promotion LLP’s aggregate shareholding in Chambal Fertilisers & Chemicals Ltd. has grown to a total of 595,073 equity shares. This represents a change in the company’s ownership position. The acquisition was executed through open market purchases.

Percentage of Shareholding

The shareholding has increased to 0.149% of the total share/voting capital of the company, compared to 0.144% before the acquisition.

Source: BSE

1234...717Page 3 of 717

© Copyright InvestyWise 2025